Instituto de Química Médica -ko ikertzaileekin lankidetzan egindako argitalpenak (54)

2023

  1. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship

    ACS Medicinal Chemistry Letters, Vol. 14, Núm. 1, pp. 18-25

2022

  1. Editorial: Cannabinoids as potential treatment for neurological diseases

    Frontiers in Neuroscience

  2. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4727-4751

2021

  1. DD04107-Derived neuronal exocytosis inhibitor peptides: Evidences for synaptotagmin-1 as a putative target

    Bioorganic Chemistry, Vol. 115

  2. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  3. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

    European Journal of Medicinal Chemistry, Vol. 210

2020

  1. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties

    European Journal of Medicinal Chemistry, Vol. 190

2019

  1. Fluoroscopic characterization of colonic dysmotility associated to opioid and cannabinoid agonists in conscious rats

    Journal of Neurogastroenterology and Motility, Vol. 25, Núm. 2, pp. 300-315

  2. Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage

    Neuropharmacology, Vol. 152, pp. 58-66

  3. New flavonoid–N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 34, Núm. 1, pp. 712-727

2018

  1. Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 156, pp. 534-553

  2. Preclinical evaluation of the effects on the gastrointestinal tract of the antineoplastic drug vincristine repeatedly administered to rats

    Neurogastroenterology and Motility, Vol. 30, Núm. 11

2017

  1. Caracterización fluoroscópica en rata de la dismotilidad colónica asociada a tratamiento con morfina

    Revista de la Sociedad Espanola del Dolor

  2. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

  3. Involvement of cannabinoid signaling in vincristine-induced gastrointestinal dysmotility in the rat

    Frontiers in Pharmacology, Vol. 8, Núm. FEB

  4. May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat

    Neurogastroenterology and Motility, Vol. 29, Núm. 3

  5. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking

    European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412

  6. Subtly Modulating Glycogen Synthase Kinase 3 β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases

    Journal of Medicinal Chemistry, Vol. 60, Núm. 12, pp. 4983-5001

  7. The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215